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The World Health Organization (WHO) convened a malaria vaccines committee (MALVAC) scientific forum from
20 to 21 February 2012 in Geneva, Switzerland, to review the global malaria vaccine portfolio, to gain consensus
on approaches to accelerate second-generation malaria vaccine development, and to discuss the need to update
the vision and strategic goal of the Malaria Vaccine Technology Roadmap. This article summarizes the forum, which
included reviews of leading Plasmodium falciparum vaccine candidates for pre-erythrocytic vaccines, blood-stage
vaccines, and transmission-blocking vaccines. Other major topics included vaccine candidates against Plasmodium
vivax, clinical trial site capacity development in Africa, trial design considerations for a second-generation malaria
vaccine, adjuvant selection, and regulatory oversight functions including vaccine licensure.
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Field trialsBackground
In 2006, the Malaria Vaccine Technology Roadmap [1]
was developed following several meetings in North
America, Europe and Africa and an extensive consulta-
tive process involving input from over 200 scientists.
This included the strategic goal to “develop and license a
malaria vaccine that has a protective efficacy of more
than 80% against clinical disease and lasts longer than
four years” by 2025. The Roadmap included 11 agreed
priority areas of research, vaccine development, key cap-
acities, and policy and commercialization.
Progress has been made in several of the Roadmap pri-
ority areas. The RTS,S/AS01 vaccine is in a Phase III
trial; many advances have been made in clinical trial and
immunoassay standardization; new antigens are in the
development pipeline, and increased efforts have been
made to share information with the research and public
health communities. Further advances have occurred in
formulation process development, strengthening good* Correspondence: moorthyv@who.int
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reproduction in any medium, provided the orclinical practice (GCP) field trial capacity, and considera-
tions of clinical development pathways for multiple
classes of malaria vaccines. Special attention has been
paid to ethics and regulatory pathways, including an effi-
cient and transparent policy process at the World Health
Organization (WHO). This process has articulated the
2015 timings for a first WHO malaria vaccine recom-
mendation on use, related to the RTS,S candidate mal-
aria vaccine [2]. Capacity has also been significantly
strengthened in ethics and regulatory oversight function
in support of clinical evaluation of candidate malaria
vaccines, especially in Africa.
Other changes have also occurred since 2006. A grati-
fying reduction in morbidity and mortality of malaria
has been observed in response to scaled-up control mea-
sures in many places, with subsequent alteration in
population disease susceptibility and immunity leading
to altered patterns of disease. The call for eradication
has increased efforts to consider impacts of interven-
tions on transmission in addition to morbidity. Another
recent landmark was the Malaria Eradication Research
Agenda (malERA) initiative, resulting in the publica-
tion of a collection of reviews highlighting key research
needs for malaria elimination, including malaria vaccinel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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product profile (TPP) for a vaccine focused on blocking
transmission [3].
The overall objective of this scientific forum convened
by WHO was to provide an update on the current
global portfolio and to agree approaches to accelerate
second-generation malaria vaccine development (for
participant list, see the Additional file 1 “List of partici-
pants at the MALVAC Meeting: 20–21 February 2012”).
The specific objectives included understanding less-
ons learned from completed malaria vaccine projects, sum-
marizing current rate-limiting steps for second-generation
malaria vaccine development, and considering innovative
ways to shorten timelines for second-generation develop-
ment. Special attention was paid to assumptions or data
that have changed since the Roadmap consultation
process occurred.Pre-erythrocytic malaria vaccine portfolios
Research and development of pre-erythrocytic vaccines
has progressed furthest, and a number of approaches in
the pipeline could contribute to improvements in the
second-generation. The importance of well-established
correlates of protection and the value of partnerships to
increase capacity were emphasized. The recent achieve-
ment of consensus on standard operating procedures
(SOPs) and protocols for design of controlled human
malaria infection (CHMI) studies represents major pro-
gress according to the priority area of clinical trial
standardization [4]. There was a call for better informa-
tion exchange with other vaccine development commu-
nities (e g, HIV and TB) on experiences with delivery
systems, adjuvants and various prime-boost regimens so
that efforts are not unnecessarily duplicated, although it
was acknowledged there are important disease-specific
issues [5].
From data generated by the leading pre-erythrocytic
vaccine groups, it is clear that it is possible with cer-
tain regimens to achieve anti-circumsporozoite IgG, as
well as CD8 T cell responses targeting another pre-
erythrocytic antigen, TRAP, that are much higher than
those seen under natural exposure and both responses
appear to associate with protection against challenge in-
fection. Adenovirus-containing heterologous prime-
boost regimens for CD8 T cell induction in humans
(using chimpanzee adenovirus strains or AdHu5) have
demonstrated some success, but concern remains about
persisting with the Ad5 vector because of widespread
occurrence of pre-existing antibodies in target popula-
tions and alternatives are actively being explored. CHMI
has been useful for decision-making and the ability
to gain a preliminary indication of efficacy in compara-
tively small CHMI studies is an important advantage forpre-erythrocytic vaccines, though CHMI studies are only
appropriate in closely monitored and highly specia-
lized settings.
Discussion focused on the minimally acceptable profile
for programmatic feasibility of prime-boost regimens;
how challenge trials can further accelerate timelines in
the future; whether field trials measuring incident infec-
tion can play a larger role; and the concept of testing
antigens to failure. Using incident infection as the
primary outcome, measured as blood film positivity or
PCR positivity, which can detect 20 parasites/mL (about
100-fold more sensitive than the most sensitive micros-
copy methods), rather than large clinical trials, is one
way to reduce trial size and shorten the development
timeframe. A key limitation of incident infection studies
is evaluation of duration of protection, which is itself a
very important efficacy outcome. There is uncertainty
as to whether impact on incident infection correlates
well with clinical protection in semi-immune individuals,
although there was a good correlation in the case of
RTS,S. It was noted that in endemic areas, trial designs
that include genotyping often add useful information,
and this aspect should be addressed whenever possible.
Consensus-based techniques for determining multiplicity
of infection and genotyping would be helpful and would
be essential if these data were to be used for WHO deci-
sion-making. The ability to clear infection before a trial
begins was discussed and remains appropriate in the
specific case of studies of incident infection.
Go/no-go criteria were also discussed. Although pre-
erythrocytic vaccines with no sterile protection in chal-
lenge trials do not warrant paediatric evaluation, it was
noted that challenge trials are generally small and confi-
dence intervals wide, so the efficacy point estimate in
any one study may not reflect the true efficacy of the
vaccine. Hence sample size calculations and confidence
intervals should be considered carefully when making
go/no-go decisions for second-generation vaccines based
on challenge trials. As more and more combinations are
highlighted as being worthy of clinical testing, the lack
of a definitive method to prove a vaccine concept prior
to challenge trials means that more challenge trials will
be needed. Robust pre-clinical and in vitro data will have
to be used to limit the number of human trials to a prac-
tical number. When considering what is failure, it is
likely that RTS,S has set the mark for what is minimally
expected, and subsequent vaccines are likely to be con-
sidered against the performance benchmarks set by RTS,
S, certainly in the pre-erythrocytic arena. It was agreed
that the status of malaria vaccine development has pro-
gressed markedly in the last few years, most clearly with
respect to the pivotal Phase III trial of RTS,S underway.
This trial was recognized as a major achievement in its
own right.
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Experience with blood-stage vaccine development has
shown that down-selection of antigens for clinical test-
ing is not a straightforward process. Multiple blood-
stage constructs have reported allele-specific protection
in secondary or exploratory analyses, though efficacy
results from any one construct have not been replicated
[6] and an urgent priority is to replicate results for the
same constructs or antigens.
There are no strong immunological correlates of pro-
tection, but a great deal of clinical trial data with blood-
stage vaccines are now available. Growth inhibitory
assays (GIA) correlate only marginally with protection,
nevertheless it is considered reasonable to use lack of
growth inhibition as a no-go criterion for a vaccine pro-
ject based on an antigen proposed to induce growth
inhibiting antibodies. Experience has not indicated that
GIA will predict field efficacy, although there is no
comparison yet available between a strongly strain-
transcending GIA response and field efficacy. A few anti-
gens have had some effect in clinical testing (i e, AMA1,
MSP2 with allele-specific protection, and some possible
efficacy for MSP3 from a Phase 1 trial requiring
confirmation), but some antigens, such as MSP1, have
repeatedly failed.
A more systematic process is needed to eliminate vac-
cine candidates with clear criteria for advancement in
the development process. These criteria may include an
understanding of the role of animal studies to predict
human responses; which immunological responses in
naïve subjects are important; correlation of functional
assays with parasite growth rates; consideration of the
importance of comparative studies; and the role of
CHMI studies for blood-stage vaccines.
The issue of how to address genetic polymorphism
was highlighted as a priority issue for this class of vac-
cines. It was suggested that antigens with extensive gen-
etic diversity should not transition into vaccine
development pipelines unless constructs inducing cross-
reactive immune responses have been produced.
Additional key topics of discussion included how
antigens should be tested to failure, the current view of
blood-stage vaccine targets for 2025, and specific
issues raised by combining pre-erythrocytic and blood-
stage constructs. It was noted that with natural infec-
tion there are stronger correlations with protection
against multiple antigens and weaker correlations for
individual antigens; however, the issues of how to disen-
tangle exposure, age and antigen-specific protection
remain challenging.
New methods of antigen presentation coupled with
new adjuvants have demonstrated the ability of recently
developed vaccines to be better than natural exposure in
inducing protective immune responses, a feature seen inthe past with few vaccines, tetanus toxoid being one ex-
ample. Presentation as a viral-like particle was a critical
success factor for HPV, and RTS,S has induced a degree
of pre-erythrocytic immunity in the field that is not
otherwise seen. The impact of the latter on semi-
immune children was greater than many anticipated,
and this would be a beneficial component of a combin-
ation vaccine. Caution was expressed in making assump-
tions about the magnitude of immune responses needed
given the low levels of responses to blood-stage antigens
that have been seen compared with the extremely high
levels of responses to pre-erythrocytic antigens. For
elimination, blood-stage vaccines may not be sufficient
by themselves, but they could be an important tool in
combination with other antigens and have the added
advantage of providing disease modification for break-
through infection in individuals with waning immunity.
Some new ligands may have been identified, and some
antibody responses have been consistently detected in
individuals who were protected. It was also pointed out
that blood-stage vaccines should not be ruled out from
the broad class of vaccines that may reduce malaria
transmission, although such an effect would need to be
demonstrated most likely in post-licensure studies.
Sexual-stage malaria vaccine portfolio and feeding assays
Two presentations highlighted progress with vaccine
constructs based on sexual stage antigens. Pfs25 remains
the only sexual stage antigen currently under clinical
evaluation, with good pre-clinical progress reported for a
construct based on Pfs48/45.
The PATH Malaria Vaccine Initiative (MVI) proposed
a minimum TPP for a sexual stage transmission blocking
vaccine that includes ≥85% efficacy (yet to be fully
defined in this context) and a duration of protection of
two years [7]. It was noted that the current TPP for
transmission blocking vaccines (TBV) is a high bar, but
practically speaking, strong tools are needed if the
goal is eradication, and it was argued that the TPP
should describe a vaccine that can meet that target.
Transmission-related epidemiological data gaps will
need to be addressed for trial design in this area, hence
the establishment of linkages between groups research-
ing transmission measures and support for epidemio-
logical studies are both critical. Only then will the links
between assay measurements and community transmis-
sion reduction be understood; this is a data gap at the
moment. Great progress has been made in recent years
with a general acceptance in malaria vaccine circles that
the issue of community benefits for TBV is not a major
hurdle for clinical or regulatory pathways. A key issue
will be establishing confidence in assays that indicate
reduction of infectivity, and what type of assay data
would lead to acceptance for decision-making. Each
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area: the standard membrane feeding assay (SMFA) may
not reflect transmission-blocking activity under field
conditions. Direct skin feeding (DSF) and direct mem-
brane feeding (DMF) assays are closer approximations
to conditions of natural exposure. There was discussion
over whether reduction of oocyst counts was an import-
ant and relevant measure of vaccine efficacy, or whether
prevention of mosquito infection was the better and
more robust endpoint.
Progress has also been made to assess and reduce vari-
ability in SMFA, including reagents such as the mos-
quito species, parasite strain, and monoclonal antibody.
Very good progress towards qualification of SMFA
was reported at the meeting, and this is a major develop-
ment for transmission blocking vaccines. The difference
between parasites and vectors in laboratory and field set-
tings was raised; techniques need to be properly devel-
oped and standardized for African settings.
Key discussion topics included how to advance further
with qualification of a membrane-feeding assay for
acceptance by decision-makers. It was agreed that this
would advance timelines for transmission blocking vac-
cines. Agreement of a formal trial design for proof-of-
concept prior to large-scale cluster randomized trials
would be very helpful. Regulatory authorities stated that
there was no requirement per se for a vaccine to provide
individual benefit and there are multiple precedents.
Examples of this concept include vaccinations of boys
with rubella vaccine to reduce incidence of congenital
rubella syndrome, and administration of primaquine
to Plasmodium falciparum cases, conferring no direct
benefit, to reduce transmission. A third example is the
requirement to receive a vaccine on entry into a non-
endemic country with no direct individual benefit but
for prevention of transmission of a disease into the non-
endemic area. There was general agreement that, given
the substantial public health benefits of a future highly
efficacious TBV and the multiple precedents, the lack of
direct benefit for an individual should not be an impedi-
ment to its development. This consensus in the scientific
community should be explored further with regulators
as appropriate.
Given the enormous dose requirements for a TBV to
be given in mass campaigns, innovative industry partner-
ships could be explored in order to develop and produce
sufficient quantities at reasonable cost. A parallel be-
tween the indirect effects of transmission blocking vac-
cines was drawn with recent developments of CMV
vaccines. A key barrier to licensure was the previous
focus on a congenital disease endpoint; consensus in the
scientific community allowed regulators to agree that
prevention of infection in pregnant women was suffi-
cient for licensure, allowing CMV vaccine developmentto move forward. It was suggested that creative
approaches be used for TBV development, and old para-
digms should not be binding. For example, one could
apply for accelerated approval based on robust data from
a qualified assay of infectivity, and use this as a tool to
determine the vaccine’s best application. The licensure
could be withdrawn if the confirmatory study did not
meet the public health needs required of a transmission
blocking vaccine.Plasmodium vivax vaccine research and development
Guidance on clinical evaluation of pre-erythrocytic and
blood-stage Plasmodium vivax vaccines was published
following the 2007 MALVAC meeting and provides
recommendations for study design, efficacy and safety
endpoints, and study participants [8]. Many principles
developed for P. falciparum apply to P. vivax, and
for TBV, all issues are identical, provided allowance is
made for relapse from hypnozoites in P. vivax. Unique
issues for P. vivax pre-erythrocytic and blood-stage
vaccines include relapses; the need to clear hypnozoites
for pre-erythrocytic vaccine evaluation; interference of
P. falciparum infections; and a theoretical risk of a shift
to increased P. falciparum infections. The reservoir of
infection for each species may be different, with neither
accessible solely through the traditional EPI age group
(for example, in areas where P. falciparum is declining,
morbidity is observed in older age groups).
In the five years that have passed since the 2007
recommendations, new issues for consideration include
the changing epidemiological context, elimination as a
goal, and the possible upcoming regulatory submission
of RTS,S for P. falciparum. There is much asymptomatic
infection, and as even low prevalence of gametocytaemia
can contribute significantly to transmission, molecular
detection of malaria infection may be required but needs
to be standardized for vaccine trials. For P. vivax, pre-
erythrocytic vaccines are needed to reduce primary
infections and relapses; a therapeutic vaccine for hypno-
zoites would be extremely useful and transmission-
blocking vaccines could counter the high transmissibility
of P. vivax. The molecular force of infection (molFOI),
defined as the number of infections with new species
clones over time [9], could be used to distinguish be-
tween different infections and relapses, and could per-
haps be a new endpoint for P. vivax vaccine trials. This
requires further discussion.
It was highlighted that P. vivax is an important disease
of adults, so vaccines must also be tested for use in
older populations. The need in many situations for a
standardized, sensitive tool that can detect all parasites,
no matter how low the concentration, was emphasized
several times.
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and studied than the P. falciparum counterpart. Presen-
tation of a recent P. vivax challenge trial led to discus-
sion on whether trial participants could be screened to
reduce the risk of relapse. Selection of low-relapsing
challenge isolates, optimal screening of volunteers and
optimal radical cure regimens will be central to any pro-
gress that can be made with P. vivax efficacy trials.
Lack of a long-term culture system was emphasized as
a critical bottleneck for P. vivax vaccine development.
The ability to maintain a clonal challenge isolate for
P. vivax would help reduce some of the complexities
inherent in naturally derived P. vivax parasite popula-
tions. Vaccines that target the hypnozoites are of inter-
est, although they are challenging to test given that
relapses can occur even years following infection. One
approach could be to use the Chesson strain, which is
known to relapse earlier, but doing so would not reflect
the real world complexity of the parasite.
More genetic diversity in transmission blocking targets
has been seen in P. vivax than P. falciparum, but
whether immune pressure causing heterogeneity occurs
with the P. vivax hypnozoites or an earlier point in the
life cycle is not known. A theoretical risk was expressed
(as has been in the past for P. falciparum) that a blood-
stage vaccine could alleviate symptoms of P. vivax with-
out clearing the parasite. In theory this could facilitate
development of severe chronic anaemia, as is seen
in children of endemic areas, at the same time allowing
ongoing transmission. Other malaria species were noted
to account for a significant burden of disease in some
settings, including Plasmodium knowlesi, Plasmodium
malariae and Plasmodium ovale.
MALVAC was encouraged to continue making P.
vivax vaccine development a priority as the burden of
P. vivax is increasing, and conventional methods for
control, such as drugs or insecticide-treated bed nets
directed against indoor resting mosquitoes, are not
effective against outdoor vectors of P. vivax and no safe
and effective drug is available for hypnozoites. It was
suggested that another meeting would be useful to
address different trial designs in different geographical
regions and how to demonstrate the potential for eli-
mination. Simultaneous consideration of P. vivax and
P. falciparum will be necessary at some point, for they
occur together in many areas.
Sustainable capacity for malaria vaccine trials: current
status and five-year view
Experts are needed in endemic countries to keep pace
with needs for basic science, clinical trials, and the regu-
latory demands associated with new products in order to
maximize gains and translate results into sustainable
public health benefit. Critical resources include a pool oftrained professionals, physical infrastructure, capacity
for GCP compliance, and functional clinical, laboratory,
regulatory, field, and logistic systems. The Malaria
Clinical Trials Alliance (MCTA) has helped to create
15 functional Phase II-IV centres (11 of which are
participating in the RTS,S Phase III study). MCTA has
facilitated government funding for research and strength-
ened staff capacity but greater capacity is required for
Phase I trials, immunological and molecular assays, and
data analysis.
Sustaining ongoing regional networks, developing sites
in areas currently lacking facilities, ensuring appropriate
human resources and retention, and integrating with
other drug or vaccine activities are areas that all need
further attention. There was much discussion about the
need to integrate maintenance costs and on-going sur-
veillance activities into facility budgets. Ownership of
trial sites is a key issue and governmental support for
trial sites, such as in Tanzania and Mali, was applauded.
National ownership is important, and sites should be
linked with universities to create teaching opportunities
and bridge the gap when trials are not ongoing. The
European and Developing Countries Clinical Trials Part-
nership (EDCTP) has taken this issue seriously and
makes capacity building an integrated activity of all
trials, including partnerships between established and
emerging institutions. Close networks and disease diver-
sification are important for sustainability. Other organi-
zations, such as the European Vaccine Initiative (EVI)
facilitate scientific and financial management training,
masters programmes, and independent grant awards,
and it recognizes achievement of successful future fund-
ing as a key output of their investment. The importance
of building strong career paths, such as through post-
doctoral positions to continue to train scientists and
build leaders in the field, is necessary to maintain insti-
tutional capacity and memory. Greater capacity in Phase
I trials will help sites with continual work flow, since
Phase III trials are far more sporadic in nature.
It was suggested that for sustainability, clinical trial
sites should be viewed as population health or clinical
research centres rather than clinical trial sites that will
run down when current trials are completed in order to
emphasize their utility across a broad scientific agenda
and range of population health challenges, over a long
time rather than only for the immediate needs of a par-
ticular trial. Most sites discussed already had a demo-
graphic surveillance system (DSS), and those that did
not are establishing them. Site capacity is also needed
in non-African countries for P. vivax vaccine studies. In
addition to clinical trials, there should be progress in
pre-clinical studies and manufacturing of vaccines as
well, as this capacity is virtually absent in Africa with the
exception of South Africa.
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vaccine development
Field trial designs for second-generation vaccines will
change if a licensed first-generation malaria vaccine
becomes available as a comparator. It is also important
to convey the need for a second-generation vaccine to
ethics committees and national governments. Given
decreases in disease incidence, sample size considera-
tions may become challenging in some settings, and
vaccine impact on older age children will require assess-
ment. Whether RTS,S is used as a comparator vaccine is
an important issue for future studies across all phases.
Careful consideration will need to be given to which is
the appropriate hypothesis to test at each stage, i e,
equivalence, superiority, or non-inferiority. More sites
may be needed in areas with higher transmission, par-
ticularly as malaria cases decrease and control measures
are used at different levels and scaled up at different
times and rates. If licensed, RTS,S would be considered
for introduction in the context of full implementation of
available control methods, and the combined interven-
tion would be expected to help to control malaria, but a
second-generation vaccine is likely to be needed to elim-
inate malaria in much of Africa. It was noted that while
continued decreases in malaria burden are highly desir-
able and achievable, one cannot predict the malaria
transmission picture in five to 10 years’ time.
Key strategic issues discussed included rate-limiting
steps for second-generation vaccine development, lessons
learned, achievements, and the appropriateness of the
current target group (infants receiving the routine EPI
schedule). WHO recommendations carry much weight,
so complexities and considerations need to be carefully
specified in relevant WHO documents to allow for flexi-
bility at the country level. It was also noted that going
outside the routine EPI schedule for vaccine administra-
tion presents a number of barriers, as the same infra-
structure for vaccine administration does not currently
exist for older age groups in many settings. If mass cam-
paigns are required, increasing the number of doses may
affect coverage obtained and impact may be quite differ-
ent from vaccine efficacy observed in clinical trials.
The importance of communication to explain the
likely impact of a partially effective vaccine was empha-
sized. It should be stressed also that there are precedents
for 50% or less efficacy with some other vaccines, such
as rotavirus vaccine in some settings, and for some end-
points such as efficacy against pneumonia for pneumo-
coccal conjugate vaccines. Furthermore, if resistance to
drugs or insecticides increases, the relative value of any
vaccine may increase even with suboptimal efficacy.
Any use of a vaccine in women of child-bearing age or
pregnant women would require careful consideration
and planning for assessment in the women and theiroffspring, but for ethical reasons delays should be
avoided in getting effective vaccines to this susceptible
target group.
Lessons learned for antigen and adjuvant selection,
access and formulation capacity
A presentation argued that antigens should be thor-
oughly investigated and optimized to reduce or prefer-
ably even eliminate the need for an adjuvant. A key
challenge is assessing how close structurally the antigen
is to the form presented in the parasite for induction
of protective responses. A clear rationale should exist
for the decision to move forward with a novel adjuvant
because of the many hurdles associated with its develop-
ment and licensure. Substantial time and resources are
required to develop new adjuvants and data on desired
immune responses and how to induce them are emer-
ging only slowly. Early clinical trials are so small that it
can be hard to make clear comparisons between differ-
ent adjuvant candidates or formulations.
A systematic approach to choosing and optimizing an
antigen with or without an adjuvant is needed. When
there are safety concerns, even if coincidental, it can be
hard to exonerate the adjuvant, reinforcing the benefit of
using adjuvants that have already been tested in large
trials or in licensed products. Microarrays may be a use-
ful tool for understanding which genes are activated dur-
ing a vaccine-induced immune response and how to
develop a long-lasting immune response. Subset analysis
of immune responses may assist in definition of epitopes
or relevant cytokines responsible for immune induced
protection. It was agreed that more research is needed
to understand immune mechanisms and their impact
on vaccine effectiveness and durability.
Regulatory considerations for second-generation
malaria vaccines
In vaccine licensure submissions to date, vaccine efficacy
has been assessed based on direct benefit, and indirect
effects have not been primary factors to support licen-
sure. However, it was highlighted that the US regulations
do not specifically require vaccines to confer direct clin-
ical benefit on the vaccine recipients. Randomized
field efficacy trials are the gold standard for demonstrat-
ing efficacy of a vaccine, including second-generation
vaccines. Some ethics review boards may consider
randomization to a placebo as unethical if there is an
approved product available as part of best practice,
meaning that comparative studies would have to be lar-
ger. There is no precedent for human challenge studies
being the primary basis for vaccine approval in the USA,
although a US Food and Drug Administration (FDA)
expert advisory committee supported challenge trials in
concept for cholera vaccines for travellers, which would
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lenge studies are limited in that they evaluate short-term
protection only and could not be done in children, one
of the target age groups for a malaria vaccine. The ani-
mal rule [11], a US regulation that outlines evidence
needed to demonstrate product efficacy when human
studies are not possible, is not applicable to malaria vac-
cines, since human efficacy studies are both ethical and
feasible. A surrogate endpoint (such as incident parasit-
aemia) could be used to support effectiveness of a vac-
cine if there is scientific consensus that it accurately
predicts the true outcome of interest. Accelerated ap-
proval (21 CFR 601 Subpart E for US regulations) based
on a surrogate endpoint that is reasonably likely to pre-
dict clinical benefit is possible for products that would
provide a meaningful therapeutic benefit over existing
treatments, but it is subject to a required confirmatory
study if there is uncertainty regarding a surrogate end-
point. Immune responses are sometimes used to infer
effectiveness of a vaccine when it cannot be measured by
cases of disease, such as if the disease incidence is very
low. However, there must be scientific consensus that the
measured immune response is meaningful, and in the case
of pre-erythrocytic malaria vaccines, it could only be used
if the antigen were the same as in the first-generation vac-
cine and immunological assays of a known immunological
correlate are sufficiently standardized and validated. Super-
iority of one vaccine over another usually cannot be deter-
mined based on immunological responses alone, and, in
general, FDA approval of superiority claims is rare.
In the discussion it was pointed out that one must dis-
tinguish between statistical validity and the meaning of
different measures to benefits for public health. WHO’s
position is that incidence of all episodes of clinical
malaria is an appropriate measure, both statistically and
in terms of relevance to public health. It is also clear that
the efficacy estimates apply only to specified durations
of follow-up. Caution was given to interpreting vaccine
efficacies based on different measures, such as risks,
hazards, or rates. Several non-malaria vaccines have
been licensed using efficacy measures based on hazards
or rate ratios, such as in the field of rotavirus vaccines.
It was pointed out that non-inferiority trials are designed
to show one product is not unacceptably worse than an-
other (rather than as good as, see Table 1 for field trial
design options). The size of the non-inferiority margin
needs justification; 5% and 10% were stated as margins
that have been previously accepted for products for
other diseases (see Table 2 for indicative sample size cal-
culations). There are no regulations specifying how safe
and effective a product must be to be licensed, and pub-
lic health considerations, such as the severity of the out-
come the product prevents or treats and the number
protected, are considered in an assessment of the overallrisks and benefits. Superiority tests will require larger
sample sizes, as do small margins for demonstration
of non–inferiority. Duration of protection will be a key
factor for second-generation vaccines in addition to the
magnitude of initial efficacy.
Discussion and recommendations on key issues
The meeting was a timely review of the landscape for
new information relevant to second-generation malaria
vaccine development and changes that may impact pri-
orities, target age groups, and study designs. The group
felt that WHO can make a unique contribution to global
efforts to shorten the timeline to the goal of a vaccine
that is at least 80% effective against malaria. As inde-
pendent and open bodies, WHO and MALVAC have im-
portant roles in gap identification, convening, consensus
building, developing guidance, and facilitating joint plan-
ning, with the goal of speeding up the development of a
second-generation vaccine.
The following key discussion points were highlighted:
 It is now timely to revisit the vision and 2025 goal
highlighted in the Malaria Vaccine Technology
Roadmap, considering the changing epidemiology in
some places.
 Malaria vaccines will not be used in isolation but
rather must be considered in the context of other
prevention measures, rapid diagnostic testing and
effective treatments and in areas where elimination
is being achieved. There may be different scenarios
where a malaria vaccine should or should not
be used.
 Some earlier assumptions, such as distribution
through routine infant programmes, need
reconsideration as a result of the changing malaria
epidemiology in some places where increasing age
of first episode of disease or low transmission could
broaden the vulnerable group and hence the target
age group for vaccination (again in the 2025
timeframe and beyond).
 Plasmodium vivax should not be forgotten as it is a
major contributing factor to malaria burden as a
whole. It presents unique and complicated issues
with the occurrence of relapse and more basic
scientific research is needed.
 Success with RTS,S should not slow research
towards a second-generation vaccine to meet the
desired 80% efficacy goal. Despite challenges due to
parasite diversity, many new vaccine candidates
look promising.
 There are still urgent unanswered questions
concerning optimal malaria assay methods, optimal
animal models and the association between assay
readouts and real-world experiences.
Table 1 Considerations of different field trial design options for second-generation malaria vaccines
Field efficacy trial options 2nd generation vs placebo 2nd generation vs 1st generation 1st/2nd generation vs 1st generation 1st/2nd generation vs 1st generation
vs placebo
Estimate of efficacy Absolute efficacy estimated. Relative efficacy estimated. Relative efficacy estimated. Absolute and relative efficacy estimated.
Type of assessment Superiority to no treatment. Non-inferiority to 1st generation or
superiority to 1st generation.
Superiority to 1st generation. Superiority to 1st generation and to
no treatment.
Limitations and Considerations May be considered unethical
to randomize to placebo,
if 1st generation vaccine is
available and recommended.
Large sample sizes may be needed.
Non-inferiority design would not show
progress towards the 80% effective
goal in the label, but could make
alternative vaccines available.
Large sample sizes may be needed.
1st and 2nd generation vaccines could
be given together or as prime-boost
strategy.
Very large sample sizes may be needed
(may not be feasible). May be considered
unethical to randomize to placebo,
if 1st generation vaccine is available
and ecommended. This design would not demonstrate
efficacy of the 2nd generation vaccine
independent of the 1st generation
vaccine.
Efficacy relative to 1st
generation vaccine would
not be known
Efficacy relative to no treatment
would not be known.
Efficacy relative to no treatment
















Table 2 Examples of total sample sizes required for field
studies of second-generation vaccine to demonstrate
non-inferiority or superiority (reported in 1,000s;
assuming intention-to-treat)
Power (1-β) : 80%
Two-sided significance level (α) : 5%
Control vaccine efficacy : 50%
Follow-up time : 2 years
Incidence rate in those not vaccinated : 1/10 PYs
New vaccine efficacy (%) Superiority Non-inferiority margin
5% 10%
50 — 28.7 7.3
55 27.4 7.0 3.2
60 6.6 3.0 1.7
65 2.9 1.6 1.1
Sample sizes are reported in 000’s and calculated using Z-test with
continuity correction.
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rationalize field trials of vaccine candidates, but
much work needs to be done on standardization in
this area. Major progress towards qualification of
one of these assays (the SMFA) was presented for
the first time at this meeting.
 Modelling can be useful in understanding the
impact of new vaccines, but it must be done in the
context of other interventions and with an
understanding of key parameters driving
uncertainties and the limitations in available
epidemiological and immunological data to guide
model parameterization.
 There do not appear to be major regulatory hurdles
to TBV from the US perspective.
 In the long-term, TBV and pre-erythrocytic
vaccines may be combined with blood-stage
vaccines in order to prevent severe disease or
death from breakthrough infections in subjects
with little or waning naturally acquired clinical
immunity.
 The need for increased basic research capacity,
trial capacity and regulatory authority capacity in
Africa is a clear requirement for sustainability.
This relates to the entire vaccine development
process, from physical infrastructure for basic
science and early clinical trials all the way
through to regulatory authorities and post-
licensure safety surveillance. The creation of
career paths to retain talent and enhance leadership
is critical.
 Partnerships between the public and private sectors
have been shown to be critical for advancing malaria
vaccine development, and should be further
strengthened.MALVAC identified a number of areas that would
benefit from further WHO involvement:
 The Malaria Vaccine Technology Roadmap,
particularly the 2025 targets from 2006 should be
reviewed and updated in light of the changing
epidemiology. This should be done with a
light touch and would include revisiting the
target groups.
 Further subpopulations should be considered, such
as migrants, transient populations, pregnant women,
immunocompromised people, and others, with the
needs of the consumer at the forefront.
 The role for TBV and gaps in their development
needs to be defined. There are precedents for
vaccines judged primarily on indirect effects.
 There is a role for a standardized assay for mosquito
infectivity that should be moved into the field
when ready.
 Replication of blood-stage vaccine efficacy results is
a priority for decision-making.
 Capacity building is needed across the spectrum of
vaccine development, from basic research through
to regulatory approval.
 The need to maintain momentum around P. vivax
was clear, particularly as it will be a key challenge
for elimination. The best format through which to
continue the work was not clear, but could include
another meeting or consultations. Consideration of
P. vivax should be linked around epidemiology,
biology, and elimination.
 It is also necessary to keep the other species, such as
P. ovale and P. malariae, in mind.
 Finally, additional consideration needs to be given to
future malaria vaccine field studies in the presence
of a licensed first-generation malaria vaccine. This
should be revisited at the time of policy
recommendations for RTS,S in 2015.Additional file
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